US corporations are navigating a delicate balance, quietly pursuing billions in refunds for import tariffs imposed by former President Donald Trump, even as Trump himself labels such efforts ‘unpatriotic.’ This discreet scramble for as much as $166 billion, plus interest, comes with significant political and legal risks, compelling most companies to remain silent on a financial windfall that could bolster their bottom lines and ease inflationary pressures.
The opportunity arose on April 20, when the Customs and Border Protection (CBP) agency opened a refund portal. This portal serves the more than 330,000 firms that paid import taxes under Trump’s use of the International Emergency Economic Powers Act (IEEPA), authority which the Supreme Court has since struck down. Despite the immense financial implications, only about 5% of the 3,000 largest publicly traded US companies, as tracked by the Russell 3000 Index, have mentioned these potential refunds in recent comments or regulatory filings, according to a Bloomberg analysis. This widespread reticence underscores the sensitivity surrounding the issue.
Political Minefield and Trump’s Stance
The primary reason for this corporate silence stems directly from the political fallout anticipated from former President Trump. He has consistently asserted that foreign firms, not US importers, bear the cost of his tariffs—an assertion that numerous studies contradict. Now, he is actively framing companies seeking these refunds as unpatriotic. ‘You’re talking about the people in many cases that hate our country, giving them back money,’ Trump told reporters at the White House, further stating, ‘It was a terrible decision.’ This rhetoric creates a challenging environment for businesses, forcing them to weigh potential financial gains against public perception and political scrutiny.
Early Disclosures and Financial Impact
Despite the prevailing caution, some of America’s most recognizable businesses have begun to offer glimpses into their involvement. Recent disclosures from companies ranging from Cardinal Health Inc. to Walmart Inc. implicitly challenge Trump’s narrative by acknowledging their payment of IEEPA tariffs or their expectation of related refunds. Among the S&P 500 companies that have presented specific amounts, documents indicate they are dealing with approximately $7.3 billion in IEEPA-related tariffs or expected refunds, according to calculations by Bloomberg. The refund process is already underway, with early filers reportedly seeing $35.5 billion flowing into their bank accounts. However, many executives are balancing the need to answer Wall Street’s financial questions with considerable uncertainty regarding the exact amounts and timing of these reimbursements.
Operational Hurdles and Legal Threats
The path to securing these refunds is not without its complexities. The US Customs agency faces the daunting task of processing claims from 330,000 importers. While some payments have arrived ‘unexpectedly quickly,’ issues with electronic filings, a legacy of the chaotic initial tariff rollout, can lead to rejections. Many importers remain skeptical that the system will efficiently handle their more complex entries. Beyond operational hurdles, a significant legal risk looms. Public statements about tariff impacts or refunds could invite class-action lawsuits from consumers who might argue they are entitled to a share of the payout. Angela Santos, who leads the customs practice at ArentFox Schiff LLP in New York, explicitly advises against such disclosures, stating, ‘I counsel against public statements regarding impacts of the tariffs or tariff refunds due to the risk of class-action suits as well as other customer and supplier considerations.’
The quiet pursuit of these substantial tariff refunds highlights a unique dilemma for US corporations: a significant financial opportunity shadowed by the specter of political condemnation and potential legal challenges. As billions continue to flow back into corporate coffers, the tension between financial prudence and public relations will likely define the pace and transparency of this ongoing reimbursement saga.
